What is Unchained Labs?
Unchained Labs, established in 2014 and based in Pleasanton, California, is dedicated to developing groundbreaking products for researchers in the biologics and gene therapy fields. Its flagship product, Optim, is recognized as the world's first and only multiplex protein stability platform, designed to significantly advance scientific discovery. The company's focus on tackling complex problems in life sciences research positions it as a key player in enabling scientific breakthroughs.
How much funding has Unchained Labs raised?
Unchained Labs has raised a total of $285M across 6 funding rounds:
Series A
$25M
Series B
$25M
Series C
$13M
Series D
$17M
Unspecified
$50M
Debt
$155M
Series A (2015): $25M with participation from TPG Biotech, Novo Ventures, and Canaan Partners
Series B (2016): $25M led by TPG Biotech, Canaan Partners, and Novo Ventures
Series C (2017): $13M supported by Canaan Partners, Novo Ventures, and TPG Biotech
Series D (2018): $17M featuring Novo Ventures, TPG Biotech, and Canaan Partners
Unspecified (2019): $50M backed by Silicon Valley Bank
Debt (2021): $155M with participation from Golub Capital and MidCap Financial
Key Investors in Unchained Labs
TPG Biotech
TPG Biotech is a global investment firm specializing in alternative assets and business growth, with a focus on identifying opportunities and building long-term value in diverse industries, including life sciences.
Canaan Partners
Canaan Partners is a venture capital firm that invests in technology and healthcare companies from seed through growth stages, with a particular interest in biopharma and digital health.
Novo Ventures
Novo Holdings, through its venture arm Novo Ventures, is a Danish investment company focused on life sciences and biotechnology, supporting innovation and growth in the sector.
What's next for Unchained Labs?
With a history of significant capital infusions, including a major strategic investment, Unchained Labs is poised for accelerated expansion. The enterprise-level funding suggests a mature stage of development, likely focused on scaling operations, enhancing product development, and broadening market reach. Future growth will likely involve further innovation in its product suite and strategic partnerships to solidify its position in the competitive biologics and gene therapy research market.
See full Unchained Labs company page
